You are here: Industry Insights > MilliporeSigma

News List

MilliporeSigma Reorganizes and Adopts New Operating Model contractpharma
February 09, 2022
Aims to support the long-term growth strategy of the Life Science business sector.
MilliporeSigma Launches New Tech and Expanded ADC Capacity ContractPharma
October 29, 2021
MilliporeSigma, the U.S. and Canadian Life Science business of Merck KGaA, Darmstadt, Germany, has launched new technology and expanded capacity to advance ADC therapies.
Inotiv Acquires Genetic Toxicology Assets from MilliporeSigma’s BioReliance® Portfolio americanpharmaceuticalreview
July 13, 2021
Inotiv acquired genetic toxicology assets from MilliporeSigma’s BioReliance® portfolio, including standard operating procedures, stock cultures, historic control data and client list.
MilliporeSigma Accelerates Scale Up of Lipids to Meet Covid Demand contractpharma
May 27, 2021
MilliporeSigma has launched a new, high-purity synthetic cholesterol product, nine months ahead of schedule to meet high demand for lipids, a key component of mRNA-based vaccines and therapeutics.
MilliporeSigma Announces VectorY as Winner of its Advance Biotech Grant americanpharmaceuticalreview
May 19, 2021
MilliporeSigma announced that VectorY has been selected as the European winner of its 2021 Advance Biotech Grant Program.
MilliporeSigma Acquires AmpTec contractpharma
January 08, 2021
MilliporeSigma has announced the acquisition of AmpTec, a Hamburg, Germany-based, mRNA contract development and manufacturing organization (CDMO).
$65 million expansion to HPAPI manufacturing facility europeanpharmaceuticalreview
September 24, 2020
The expansion will be specifically designed to manufacture high-potency active pharmaceutical ingredients (HPAPIs) and complex antibody-drug conjugates (ADCs).
MilliporeSigma Expands HPAPI and ADC Mfg. Capabilities contractpharma
September 18, 2020
$65 million investment to expand facility near Madison, WI will allow large-scale manufacturing of increasingly potent compounds.
MilliporeSigma Invests $20 Million in New Switzerland Laboratory americanpharmaceuticalreview
July 23, 2020
MilliporeSigma has announced plans to build a new, $20 million laboratory facility in Buchs, Switzerland to support its growing reference materials business. MilliporeSigma anticipates that about two dozen jobs will be created.
MilliporeSigma Opens M Lab Collaboration Center in Shanghai contractpharma
July 13, 2020
Offers customizable solutions to help advance drug development, including pilot scale and process development support labs that offer non-GMP lab space.

Previous page 1 2 3 4 Next page